AbCellera Biologics, Inc.

AbCellera Biologics, Inc. faced a notable decline in stock value, contrasting with the broader market's performance. Despite recent setbacks and negative results over ten quarters, the company has shown strong year-over-year growth. Institutional investors maintain significant holdings, indicating ongoing confidence in its fundamentals amid current challenges.

AbCellera Biologics, Inc. saw a notable rise in stock performance on October 15, 2025, reaching an intraday high. Despite a strong annual return, the company has struggled with negative results over the past ten quarters and faces financial challenges, though institutional holdings have increased, reflecting investor confidence.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 6.51 on October 8, 2025, reflecting significant growth from its previous low. The company has outperformed the S&P 500 over the past year, although it continues to report losses and has notable financial metrics indicating its market position.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 6.41 on October 3, 2025, reflecting a strong performance over the past year. The company, with a market capitalization of USD 1,246 million, has outperformed the S&P 500, despite reporting losses and a negative return on equity.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 5.97 on October 1, 2025, reflecting a significant increase from its previous low. The company has shown a 69.8% rise in stock price over the past year, despite being in a loss-making position and lacking dividends.

AbCellera Biologics, Inc. saw a notable rise in stock performance on September 30, 2025, with significant gains over the past week and month. Despite impressive annual returns, the company has faced challenges, including negative results for ten consecutive quarters and declining profits, alongside strong institutional investor confidence.

AbCellera Biologics, Inc. has demonstrated strong stock performance, significantly outperforming the S&P 500 over various timeframes. Despite facing challenges with negative results for the past ten quarters and concerning financial metrics, institutional holdings indicate confidence from larger investors, reflecting the company's complex market position.

AbCellera Biologics, Inc. has recently adjusted its market evaluation, with its stock priced at $4.51. Over the past year, the company has achieved a notable 64.6% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and cautious sentiments.

AbCellera Biologics, Inc. has seen notable stock activity, achieving significant gains over various timeframes while outperforming the S&P 500. Despite facing challenges with consecutive quarterly losses and negative financial metrics, strong institutional holdings indicate investor confidence in the company's market position.